Evidence map›Paper›PMID 41981278›Full record

ArticleCancer gene therapy2026

WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m

Ruxue Shi, Kai Gu, Haichuan Li, Qingwei Sun, Xinyu Wu, Shuhong Huang, Qingxia Hu

Abstract read
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ruxue ShiShandong Provincial Hospital of Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID http://orcid.org/0009-0000-8555-4069
Kai GuSchool of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Haichuan LiSchool of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Qingwei SunSchool of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID http://orcid.org/0009-0006-8857-929X
Xinyu WuCollege of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Shuhong HuangSchool of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China. shuhonghuang@sdfmu.edu.cn.ORCID http://orcid.org/0000-0001-6298-6192
Qingxia HuShandong Provincial Hospital of Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China. qxhu@sdfmu.edu.cn.ORCID http://orcid.org/0000-0002-2508-5552

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82002691Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation) ZR2020QC068
6 · The paper itself

Abstract

Castration-resistant prostate cancer (CRPC) is one of the most prevalent cancers in men. The new generation androgen receptor (AR) inhibitor enzalutamide can improve the therapeutic effectiveness of patients with CRPC. However, these patients eventually develop acquired enzalutamide resistance (ENZR), and the mechanisms underlying resistance are not well understood. Wilms' tumor 1-associating protein (WTAP) plays an important role in m

Indexed as

BenzamidesCell Cycle ProteinsDrug Resistance, NeoplasmNitrilesPhenylthiohydantoinProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantProto-Oncogene Proteins c-aktRNA Splicing FactorsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceBenzamidesCell Cycle ProteinsenzalutamideNitrilesPhenylthiohydantoinProto-Oncogene Proteins c-aktReceptors, AndrogenRNA Splicing FactorsWTAP protein, human

Identifiers

PMID41981278
PMCPMC13109060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.